In a phase 4 trial, 60-minute pegloticase infusions co-administered with methotrexate demonstrated safety, tolerability, and efficacy comparable to the standard 120-minute duration, with a 67% treatment...
The FDA recently announced the approval of rilzabrutinib tablets for adults with persistent or chronic immune thrombocytopenia who did not respond to immunoglobulins, anti-D therapy, or corticosteroids.
...
Biologic therapies have revolutionized the treatment of inflammatory arthritis, but their complexity demands practical understanding from clinicians across specialties.
Post hoc analyses of the phase 2 NOBILITY trial reveal that adding obinutuzumab to standard lupus nephritis therapy enhances kidney preservation and reduces glucocorticoid reliance.
Robert Wermers, MD, and Monica Richey, MSN, ANP-bc, provide management updates and guidelines for clinicians who are treating patients with osteoporosis and osteopenia in their session at the Practical...
Osteoarthritis is a common chronic and degenerative disease among adults. A group of experts estimated the disease’s burden spanning two decades and the projection of burden to 2050.
Despite being approved for use, consensus among the real-world data on the use of IL-23 inhibitors in psoriatic disease has been lacking; therefore, researchers recently examined the drug survival and...
